What's new

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised

Apr 25, 2025 - 13:27
 0
Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout

Next Article

Protein lifts Danone in North America

Related Posts

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 8, 2025  0

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0

Product-information (QRD) templates - Human

Product-information (QRD) templates - Human

Apr 14, 2025  0